Cancer CD39 drives metabolic adaption and mal-differentiation of CD4+ T cells in patients with non-small-cell lung cancer
Ying Wang, Mengdi Liu, Lei Zhang, Xiyu Liu, Huiyan Ji, Yan Wang, Jun Gui, Yan Yue, Zhenke Wen · 2023
Read Cancer CD39 drives metabolic adaption and mal-differentiation of CD4+ T cells in patients with non-small-cell lung cancer by Ying Wang, Mengdi Liu, Lei Zhang, Xiyu Liu, Huiyan Ji, Yan Wang, Jun Gui, Yan Yue, Zhenke Wen (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10703826.txt.
Description
A lung tumor can disarm the T cells sent to kill it by handing them its own enzyme. Ying Wang and eight co-authors traced the hand-off in a 2023 paper on non-small-cell lung cancer. The enzyme is CD39, already a drug target in trials, shown here working directly on T cell fate.
Tumor cells package CD39 into exosomes and pass them to helper T cells, draining their ATP and over-activating an energy alarm. The starved cells then mature wrong: pushed toward regulatory roles and away from effector ones. Removing CD39 from the tumor broke the effect in lab models and patient-derived organoids. Alone or with PD-1 immunotherapy, the removal restored effector cells and slowed organoid tumor growth. The authors give CD39 inhibitors a sharper rationale: block the hand-off, and the immune system's own soldiers keep their training.
Catalog record
| CREATOR | Ying Wang, Mengdi Liu, Lei Zhang, Xiyu Liu, Huiyan Ji, Yan Wang, Jun Gui, Yan Yue, Zhenke Wen |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |